Overview
With $400 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Our seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. We invest in companies developing novel products for significant unmet medical needs more >
Portfolio
Recent News
- Wed, Jan 2nd, 2019 — Intact Vascular Announces Enrollment Completion of TOBA II BTK Clinical
- Tue, Dec 18th, 2018 — Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line
- Thu, Nov 29th, 2018 — CardioFocus Completes Enrollment In HeartLight® X3 Trial
- Tue, Nov 27th, 2018 — Apollo Endosurgery Announces First Commercial Shipment of the OverStitch™ Sx Endoscopic…
- Tue, Nov 20th, 2018 — Vertiflex Announces Publication of Data Analysis Showing 85% Reduction in Patients Using Opioids…
- Tue, Nov 6th, 2018 — Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial
- Mon, Nov 5th, 2018 — Intact Vascular Hires Industry Veteran Steve MacKinnon as Vice President of Sales
- Mon, Oct 15th, 2018 — On Target Laboratories Announces Publication Supporting Use of OTL78 to Highlight Prostate…
- Thu, Oct 11th, 2018 — H.I.G. BioHealth Partners Completes Sale of HyperBranch Medical Technology, Inc. to Stryker
- Mon, Aug 6th, 2018 — Symposium to Explore the Impact of Vascular Dissections on Critical Limb Ischemia Patients…